NFKB1 and nonpapillary renal cell carcinoma: PERK blockade using pharmacological or genetic approaches completely prevents sunitinib-induced expression of IL-6, IL-8 and TNF-α, whereas NF-κB inhibition reinstates sensitivity of ccRCC cells to sunitinib both in vitro and in vivo.